Efficacy of boceprevir, an NS3 protease inhibitor, in combination withpeginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Number of pages12
JournalThe Lancet
Volume376
Publication statusPublished - 2010

Cite this